Print

Addex Therapeutics (ADXN.SW) Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting  
10/11/2012 8:55:31 AM

GENEVA, SWITZERLAND--(Marketwire - October 11, 2012) - Addex Therapeutics / Addex Scientists Present New Data on Oral Small Molecule Programs Targeting GPCR at the Society for Neuroscience 2012 Meeting. Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

Research highlights include data from Addex' programs in Alzheimer's, Parkinson's, psychiatry indications and post-traumatic stress disorder

Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today the company will present data from three of its innovative allosteric modulation programs targeting G-protein coupled receptors (GPCRs) at the Society for Neuroscience 2012 meeting next week (October 13-17). The programs that will be showcased at the meeting include:

ADX92639: a potent and selective negative allosteric modulator (NAM) of metabotropic glutamate receptor 2 (mGluR2) that has the potential to treat a number of diseases, including improving cognition and Alzheimer's disease. In an oral presentation at the conference, data demonstrating ADX92639-mediated improvement in recognition memory in validated rodent models of Alzheimer's disease will be discussed. The selectivity of ADX92639 for mGluR2 differentiates the compound from other approaches targeting this important receptor.

Dipraglurant: a clinical stage potent oral small molecule NAM targeting mGluR5 that has the potential to treat a variety of indications, including Parkinson's disease levodopa-induced dyskinesia (PD-LID), dystonia, anxiety, and depression. Data will be presented in two poster sessions, one on the translational value of the MPTP non-human primate model of PD-LID to the clinical utility of dipraglurant; and a second about the treatment of non dyskinetic complications with dipraglurant, i.e., affective disorders and compulsive behaviors.

ADX71743: a potent and selective NAM of mGluR7. Data generated with this unique molecule will be presented in a poster at the conference, unraveling some key physiological roles of mGluR7, and suggesting that its pharmacological blockade may represent a new avenue for the treatment of anxiety, drug abuse and cognitive function disorders, such as depression and post-traumatic stress disorder (PTSD).

"Each of these exciting programs originates from our proprietary allosteric modulation technology platform. Our research and the data presented at the Conference demonstrate the significant progress we are making in translating the promise of allosteric modulation towards a new class of oral small molecule therapeutics. These innovative, potent and highly selective allosteric modulators are being developed to address important GPCR targets that have previously been deemed "undruggable" using conventional approaches." explained Dr Graham Dixon, CSO of Addex Therapeutics. "We believe that these allosteric modulators have the potential to transform the treatment of several important neurological diseases that are not adequately being treated with the current standards of care."

Society for Neuroscience 2012 presentations include:

Monday, Oct 15, 2012
9:00 - 10:00 AM

ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7 (mGluR7), Hall F-J Program/Poster #359.06/Y12

Tuesday, Oct 16, 2012
8:00 - 9:00 AM

Effect of the metabotropic glutamate receptor type 5 negative allosteric modulator dipraglurant on non-motor symptoms of Parkinson's disease, Hall F-J Program/Poster #546.09/F41

4:15 - 4:30 PM
Nanosymposium

620 Alzheimer's Disease: In vivo Therapeutics ADX92639, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 2 (mGluR2) improves recognition memory in rodent models relevant to Alzheimer's disease, Room 395- oral presentation


Wednesday, Oct 17, 2012
10:00 - 11:00 AM

Antidyskinetic effects of the mGluR5 receptor negative allosteric modulator, dipraglurant: A translational approach in the MPTP macaque model of levodopa-induced dyskinesia and in patients with Parkinson's disease, Hall F-J Program/Poster #758.19/L13

Addex Therapeutics (www.addextherapeutics.com) discovers and develops an emerging class of small molecule drugs, called allosteric modulators, which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs. The Company uses its proprietary discovery platform to address receptors and other proteins that are recognized as attractive targets for modulation of important diseases with unmet medical needs. The Company's two lead products are being investigated in Phase 2 clinical testing: dipraglurant (ADX48621, an mGluR5 negative allosteric modulator or NAM) is being developed by Addex to treat Parkinson's disease levodopa-induced dyskinesia (PD-LID); and ADX71149 (mGluR2 positive allosteric modulator or PAM) is being developed by our partner Janssen Pharmaceuticals Inc. to treat schizophrenia and anxiety seen in patients suffering from major depressive disorder. Addex also is advancing several preclinical programs including: GABABR PAM for overactive bladder and other disorders; mGluR4 PAM for Parkinson's, MS, anxiety and other diseases. In addition, Addex is applying its proprietary discovery platform to identify highly selective and potent allosteric modulators of a number of both GPCR and non-GPCR targets that are implicated in diseases of significant unmet medical need.

Disclaimer: The foregoing release may contain forward-looking statements that can be identified by terminology such as "not approvable", "continue", "believes", "believe", "will", "remained open to exploring", "would", "could", or similar expressions, or by express or implied discussions regarding Addex Therapeutics, formerly known as, Addex Pharmaceuticals, its business, the potential approval of its products by regulatory authorities, or regarding potential future revenues from such products. Such forward-looking statements reflect the current views of Addex Therapeutics regarding future events, future economic performance or prospects, and, by their very nature, involve inherent risks and uncertainties, both general and specific, whether known or unknown, and/or any other factor that may materially differ from the plans, objectives, expectations, estimates and intentions expressed or implied in such forward-looking statements. Such may in particular cause actual results with allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR or other therapeutic targets to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR or other therapeutics targets will be approved for sale in any market or by any regulatory authority. Nor can there be any guarantee that allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR or other therapeutic targets will achieve any particular levels of revenue (if any) in the future. In particular, management's expectations regarding allosteric modulators of mGluR2, mGluR4, mGluR5, GABABR or other therapeutic targets could be affected by, among other things, unexpected actions by our partners, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; competition in general; government, industry and general public pricing pressures; the company's ability to obtain or maintain patent or other proprietary intellectual property protection. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Addex Therapeutics is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise, except as may be required by applicable laws.

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Addex Therapeutics via Thomson Reuters ONE

[HUG#1648198]


Tim Dyer
Chief Financial Officer
Addex Therapeutics
+41 22 884 15 61
Email Contact


//-->